Adil Daud, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Articles

Treatment Optimization for Patients With Melanoma

June 23rd 2020

Future Treatment Landscape for Melanoma

June 23rd 2020

Promising Late-Stage Trials in Melanoma

June 23rd 2020

Targeted Therapy Versus IO for Relapsed/Refractory Melanoma

June 23rd 2020

Novel Approaches for Relapsed/Refractory Melanoma

June 23rd 2020

Management of Brain Metastases in Melanoma

June 23rd 2020

I/O Dosing Schedules in Metastatic Melanoma

June 23rd 2020

Novel Therapies for Metastatic Melanoma

June 23rd 2020

Systemic Therapy for Metastatic Melanoma

June 23rd 2020

Adjuvant Therapy for Melanoma: Safety and Efficacy

June 23rd 2020

Adjuvant Therapy for Melanoma: Ongoing Studies of Interest

June 23rd 2020

Adjuvant Data Explored for Locally Advanced Melanoma

June 23rd 2020

Neoadjuvant Data Explored for Locally Advanced Melanoma

June 23rd 2020

pCR and Neoadjuvant Therapy for Melanoma

June 23rd 2020

Molecular Testing in Locally Advanced Melanoma

June 23rd 2020

Identifying Patients for Neoadjuvant Melanoma Therapy

June 23rd 2020

Optimal Management of Locally Advanced Melanoma

June 23rd 2020

Dr. Daud on Dabrafenib/Trametinib Vs Immunotherapy in Melanoma

December 5th 2019

Adil Daud, MD, discusses the combination of dabrafenib and trametinib versus immunotherapy in patients with BRAF V600-mutant metastatic melanoma.

Dr. Daud on Interferon Gamma as a Biomarker in Melanoma

November 8th 2019

Adil Daud, MD, clinical professor, Department of Medicine (Hematology/Oncology) and director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses research evaluating interferon gamma as a potential biomarker of response in melanoma.

Dr. Daud Discusses the Immunogenicity of Melanoma

May 17th 2019

Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity of melanoma.